

分担研究報告書

肝細胞への分化誘導に適したヒト iPS 細胞のスクリーニング

分担研究者 梅澤 明弘

独立行政法人 国立成育医療研究センター 生殖・細胞医療研究部長

研究要旨：細胞を用いた医薬品開発において、様々な安全性・有効性評価系の確立の重要性は ヒト iPS 細胞の登場に伴い期待が高まってきている。我々はこれまでに様々な組織由来のヒト間葉系幹細胞を樹立し、安定した幹細胞培養条件の開発を行ってきた。本研究ではこうした実績と経験を生かし、創薬研究への応用が期待されているヒト iPS 細胞に関して、肝細胞への分化誘導に適した細胞のスクリーニングを担当する。ヒト iPS 細胞等の幹細胞の再現性ある安定した細胞培養系の確立のための品質管理・品質評価法の開発をおこない、特にヒト胎児肺組織由来細胞から樹立した 500 種類の iPS 細胞を用いて肝細胞への分化誘導に適した細胞株の選別を行った。本年度は、バイオインフォマティクス的手法を用いた包括的な解析を行い、再現性のあるスクリーニング手法の確立に務めた。

## A. 研究目的

新薬開発では、開発費に 1000 億円超、期間に 10～15 年を要する。また、約 2 万件の候補化合物の中から、薬効・毒性などの評価を経て医薬品として承認を受けるのは 1 件程度である。この過程でしばしば問題となるのが薬物誘発性肝障害（肝毒性）であるが、医薬品の開発プロセスの早期に肝毒性を確度良く予測することは、創薬コスト削減・期間短縮・創薬シーズのヒット率の向上をもたらし、我が国の基幹産業のひとつである製薬産業の国際競争力向上に繋がると期待される。ヒト初代培養肝細胞の利用により肝毒性評価の向上が見込まれるものの、我が国においては入手が困難であり、安定供給、継続性の観点からその利用には限界がある為、より安定かつ容易に使用できる肝毒性評価系の確立が望まれている。そこで本研究では、①肝細胞に

分化しやすい iPS 細胞株のスクリーニング法の開発、②ヒト iPS 細胞から成熟肝細胞を創出する技術開発、および③ヒト iPS 細胞由来分化誘導肝細胞を利用した肝毒性評価系の確立を行う。

## B. 研究方法

### (1) ゲノム安定性評価法の確立

培養過程における継代、凍結等ゲノム安定性に与える影響について、核型解析ならびにアレイ CGH により検定する。

### (2) 肝分化指向性評価法開発

ヒト iPS 細胞の継代過程における経時変化について、肝分化マーカーの発現プロファイルを定量的 PCR により評価し、表面マーカーは免疫組織学的解析により行うことで、肝分化指向性評価法の検定を行う。

### (3) データの統合及びバイオインフォマティックス的手法を用いた解析

アレイCGH、マイクロアレイ等で得られた網羅的な発現データに付いて主成分解析、クラスタリング解析を行い、有用な評価指標を抽出する。また、エピゲノム解析を行う。

#### (倫理面への配慮)

当研究所においては、ヒト間葉系細胞の樹立と基礎研究応用に関し、既に倫理審査を受け、承認を受けている（国立成育医療センター研究所、受付番号 25、26 及び 27、平成 15 年 1 月承認、受付番号 49、平成 15 年 10 月承認、受付番号 55、平成 15 年 11 月承認、受付番号 88、89、90、91、平成 16 年 7 月承認、受付番号 55、平成 16 年 11 月追加承認、受付番号 146、平成 17 年 4 月承認、受付番号 156、平成 17 年 7 月承認、受付番号 197、201、平成 18 年 6 月承認、受付番号 237、238、平成 19 年 11 月承認、受付番号 293、315、平成 20 年 10 月承認、受付番号 319、平成 20 年 12 月承認、承認番号 350、平成 22 年 1 月）。また、それぞれの組織については倫理的な手続きおよび考え方が年次毎に異なると予想され、「ヒト幹細胞等を用いる臨床研究に関する指針」に従い、最新の社会的な影響を十分に考慮する。なお、研究協力者に倫理専門家を加え、本研究遂行にあたって新たな倫理的問題が生じないように、常にモニタリングを行い、必要に応じて意見交換を行う。

実験動物を用いる研究については、国立成育医療センター研究所動物実験指針に準拠して研究を実施する（承認番号 2003-002,2005-003）。特に、動物愛護と動物福祉の観点から実験動物使用は、目的に合致した最小限にとどめる。またその際、麻酔等手段により苦痛を与えない等の倫理的配慮をおこなう。実験者は、

管理者と相互協力のもと適切な環境のもと飼育管理を行う。

## C. 研究結果

### (1) ゲノム安定性評価法

ヒト iPS 細胞の長期にわたる未分化性評価に加え、ゲノムレベルでの変異について検証した。その結果、染色体レベルおよびゲノムレベルで異常はほとんど検出されなかった。

### (2) 肝分化指向性評価法開発

成育医療研究センターが有する iPS 細胞について、継代数に応じて肝分化マーカーの遺伝子発現を、ヒト肝細胞での発現を基準として定量 PCR を行った。その結果肝分化マーカーの発現はヒト肝細胞と比較していずれも同等もしくはそれ以上の発現が認められ、継代数による大きな変化は認めなかった。細胞表面マーカーについてもいずれも陽性であり未分化性を維持していることが示された。

### (3) データの統合及びバイオインフォマティックス的手法を用いた解析

アレイCGH、マイクロアレイ等で得られた網羅的な発現データに付いて主成分解析、クラスタリング解析を行い、有用な評価指標を抽出した。また、エピゲノムの発現様式も視野に入れた解析を行った結果、iPS 細胞の分化傾向はメチレーションによって明確に規定されている箇所があることを明らかにした。

## D. 考察

ヒト iPS 細胞の肝分化マーカーによるスクリーニング系について検証し、その培養技術について検討した。また最もシビアな問題として考えられているゲノム変異について、染色体レベルおよびゲノムレベルでの検証法を確立した。本年度

は特にエピゲノムまで解析範囲を広げた手法を確立した。この評価系で染色体異常を認める iPS 細胞の細胞形質を詳細に解析し、正常な iPS 細胞と比較検証する基盤ができ、創薬開発に必要な良質な iPS 細胞由来肝細胞とは何かということの規定することが可能となる。また肝分化指向性評価とゲノム安定性評価による結果は、現在の培養システムがヒト iPS 細胞を長期にわたって安定的に培養できていることを示している。今後、フィーダフリー、血清フリー培養条件で長期安定的に肝分化指向性を維持できる細胞培養条件が課題となる。その評価を行う対象となる培養システムが確立できたことは、フィーダフリー、血清フリー培養下で長期にわたって安定した培養環境を構築し、品質管理・評価法の確立へとつながると考えられた。

## E. 結論

ヒト iPS 細胞の継代による経時的評価をし、肝細胞の細胞特性が維持できているかを検証した。さらにゲノムレベル、エピゲノムでの安定性に関する解析を加え品質評価技術の基盤整備が整った。今後はフィーダフリー、血清フリー培養条件下での細胞についてこの評価系を応用して、創薬開発に資する安定した肝細胞スクリーニング技術の開発を行っていく。

## F. 研究発表

### 1. 論文発表

Sugawara T, Nishino K, Umezawa A, Akutsu H. Investigating cellular identity and manipulating cell fate using induced pluripotent stem cells. *Stem Cell Res Ther.* 3(2):8, 2012.

Yokoi T, Seko Y, Yokoi T, Makino H,

Hatou S, Yamada M, Kiyono T, Umezawa A, Nishina H, Azuma N. Establishment of functioning human corneal endothelial cell line with high growth potential. *PLoS One.* 7(1):e29677, 2012.

Gojo S, Toyoda M, Umezawa A. Tissue engineering and cell-based therapy toward integrated strategy with artificial organs. *J Artif Organs.* 14(3):171-177, 2011.

Kami D, Takeda S, Makino H, Toyoda M, Itakura Y, Gojo S, Kyo S, Umezawa A, Watanabe M. Efficient transfection method using deacylated polyethylenimine-coated magnetic nanoparticles. *J Artif Organs.* 14(3):215-222, 2011.

Isshiki H, Sato K, Horiuchi K, Tsutsumi S, Kano M, Ikegami H, Abe H, Umezawa A, Aburatani H, Toyama Y. Gene expression profiling of mouse growth plate cartilage by laser microdissection and microarray analysis. *J Orthop Sci.* 16(5):670-672, 2011.

Numasawa Y, Kimura T, Miyoshi S, Nishiyama N, Hida N, Tsuji H, Tsuruta H, Segawa K, Ogawa S, Umezawa A. Treatment of human mesenchymal stem cells with angiotensin receptor blocker improved efficiency of cardiomyogenic transdifferentiation and improved cardiac function via angiogenesis. *Stem Cells.* 29(9):1405-1414, 2011.

Takezawa Y, Yoshida K, Miyado K, Sato M, Nakamura A, Kawano N,

- Sakakibara K, Kondo T, Harada Y, Ohnami N, Kanai S, Miyado M, Saito H, Takahashi Y, Akutsu H, Umezawa A.  $\beta$ -catenin is a molecular switch that regulates transition of cell-cell adhesion to fusion. *Sci Rep*. 1:68, 2011.
- Nakamura A, Miyado K, Takezawa Y, Ohnami N, Sato M, Ono C, Harada Y, Yoshida K, Kawano N, Kanai S, Miyado M, Umezawa A. Innate immune system still works at diapause, a physiological state of dormancy in insects. *Biochem Biophys Res Commun*. 410(2):351-357, 2011.
- Hankowski KE, Hamazaki T, Umezawa A, Terada N. Induced pluripotent stem cells as a next-generation biomedical interface. *Lab Invest*. 91(7):972-977, 2011.
- Saito S, Onuma Y, Ito Y, Tateno H, Toyoda M, Hidenori A, Nishino K, Chikazawa E, Fukawatase Y, Miyagawa Y, Okita H, Kiyokawa N, Shimma Y, Umezawa A, Hirabayashi J, Horimoto K, Asashima M. Possible linkages between the inner and outer cellular states of human induced pluripotent stem cells. *BMC Syst Biol*. 5 Suppl 1:S17, 2011.
- Tateno H, Toyota M, Saito S, Onuma Y, Ito Y, Hiemori K, Fukumura M, Matsushima A, Nakanishi M, Ohnuma K, Akutsu H, Umezawa A, Horimoto K, Hirabayashi J, Asashima M. Glycome diagnosis of human induced pluripotent stem cells using lectin microarray. *J Biol Chem*. 286(23):20345-20353, 2011.
- Higuchi A, Ling QD, Ko YA, Chang Y, Umezawa A. Biomaterials for the feeder-free culture of human embryonic stem cells and induced pluripotent stem cells. *Chem Rev*. 111(5):3021-3035, 2011.
- Hasebe Y, Hasegawa S, Hashimoto N, Toyoda M, Matsumoto K, Umezawa A, Yagami A, Matsunaga K, Mizutani H, Nakata S, Akamatsu H. Analysis of cell characterization using cell surface markers in the dermis. *J Dermatol Sci*. 62(2):98-106, 2011.
- Nishino K, Toyoda M, Yamazaki-Inoue M, Fukawatase Y, Chikazawa E, Sakaguchi H, Akutsu H, Umezawa A. DNA methylation dynamics in human induced pluripotent stem cells over time. *PLoS Genet*. 7(5):e1002085, 2011.
- Sato B, Katagiri YU, Miyado K, Okino N, Ito M, Akutsu H, Okita H, Umezawa A, Fujimoto J, Toshimori K, Kiyokawa N. Lipid rafts enriched in monosialylGb5Cer carrying the stage-specific embryonic antigen-4 epitope are involved in development of mouse preimplantation embryos at cleavage stage. *BMC Dev Biol*. 11:22, 2011.
- Yazawa T, Kawabe S, Inaoka Y, Okada R, Mizutani T, Imamichi Y, Ju Y, Yamazaki Y, Usami Y, Kuribayashi M, Umezawa A, Miyamoto K. Differentiation of mesenchymal stem cells and embryonic stem cells into steroidogenic cells using steroidogenic factor-1 and liver receptor homolog-1. *Mol Cell Endocrinol*. 336(1-2):127-132, 2011.

Nishi M, Akutsu H, Masui S, Kondo A, Nagashima Y, Kimura H, Perrem K, Shigeri Y, Toyoda M, Okayama A, Hirano H, Umezawa A, Yamamoto N, Lee SW, Ryo A. A distinct role for Pin1 in the induction and maintenance of pluripotency. *J Biol Chem*. 286(13):11593-11603, 2011.

Sato T, Iso Y, Uyama T, Kawachi K, Wakabayashi K, Omori Y, Soda T, Shoji M, Koba S, Yokoyama S, Fukuda N, Saito S, Katagiri T, Kobayashi Y, Takeyama Y, Umezawa A, Suzuki H. Coronary vein infusion of multipotent stromal cells from bone marrow preserves cardiac function in swine ischemic cardiomyopathy via enhanced neovascularization. *Lab Invest*. 91(4):553-564, 2011.

G. 知的財産権の出願・登録状況  
該当事項なし

研究成果の刊行に関する一覧表

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Takayama K, Inamura M, Kawabata K, Katayama K, Higuchi M, Tashiro K, Nonaka A., Sakurai F, Hayakawa T, Furue MK, Mizuguchi H.	Efficient generation of functional hepatocytes from human embryonic stem cells and induced pluripotent stem cells by HNF4 $\alpha$ transduction.	Mol. Ther.	20(1)	127-137	2012
Kawabata K., Inamura M., Mizuguchi H.	Efficient Hepatic Differentiation of Human iPS Cells by Gene Transfer.	Methods Mol Biol	826	115-124	2012
Sugawara T, Nishino K, Umezawa A, Akutsu H.	Investigating cellular identity and manipulating cell fate using induced pluripotent stem cells.	Stem Cell Res Ther	3(2)	8	2012
Yokoi T, Seko Y, Yokoi T, Makino H, Hatou S, Yamada M, Kiyono T, Umezawa A, Nishina H, Azuma N.	Establishment of functioning human corneal endothelial cell line with high growth potential.	PLoS One	7(1):	e29677	2012
Takayama K, Inamura M, Kawabata K, Tashiro K, Katayama K, Hayakawa T, Furue MK, Mizuguchi H.	Efficient and selective generation of two distinct endoderm lineages from human ES and iPS cells by differentiation stage-specific SOX17 transduction.	PLoS One	6(7)	e21780	2011
Gojo S, Toyoda M, Umezawa A.	Tissue engineering and cell-based therapy toward integrated strategy with artificial organs.	J Artif Organs	14(3)	171-177	2011
Kami D, Takeda S, Makino H, Toyoda M, Itakura Y, Gojo S, Kyo S, Umezawa A, Watanabe M.	Efficient transfection method using deacylated polyethylenimine-coated magnetic nanoparticles.	J Artif Organs	14(3)	215-222	2011
Isshiki H, Sato K, Horiuchi K, Tsutsumi S, Kano M, Ikegami H, Abe H, Umezawa A, Aburatani H, Toyama Y.	Gene expression profiling of mouse growth plate cartilage by laser microdissection and microarray analysis.	J Orthop Sci	16(5)	670-672	2011

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Numasawa Y, Kimura T, Miyoshi S, Nishiyama N, Hida N, Tsuji H, Tsuruta H, Segawa K, Ogawa S, Umezawa A.	Treatment of human mesenchymal stem cells with angiotensin receptor blocker improved efficiency of cardiomyogenic transdifferentiation and improved cardiac function via angiogenesis.	Stem Cells	29(9)	1405-1414	2011
Gokoh M, Nishio M, Nakamura N, Matsuyama S, Nakahara M, Suzuki S, Mitsumoto M, Akutsu H, Umezawa A, Yasuda K, Yuo A, Saeki K.	Early senescence is not an inevitable fate of human-induced pluripotent stem-derived cells.	Cell Reprogram	13(4)	361-370	2011
Takezawa Y, Yoshida K, Miyado K, Sato M, Nakamura A, Kawano N, Sakakibara K, Kondo T, Harada Y, Ohnami N, Kanai S, Miyado M, Saito H, Takahashi Y, Akutsu H, Umezawa A.	$\beta$ -catenin is a molecular switch that regulates transition of cell-cell adhesion to fusion.	Sci Rep	1	68	2011
Nakamura A, Miyado K, Takezawa Y, Ohnami N, Sato M, Ono C, Harada Y, Yoshida K, Kawano N, Kanai S, Miyado M, Umezawa A.	Innate immune system still works at diapause, a physiological state of dormancy in insects.	Biochem Biophys Res Commun	410(2)	351-357	2011
Hankowski KE, Hamazaki T, Umezawa A, Terada N.	Induced pluripotent stem cells as a next-generation biomedical interface.	Lab Invest	91(7)	972-977	2011
Saito S, Onuma Y, Ito Y, Tateno H, Toyoda M, Hidenori A, Nishino K, Chikazawa E, Fukawatase Y, Miyagawa Y, Okita H, Kiyokawa N, Shimma Y, Umezawa A, Hirabayashi J, Horimoto K, Asashima M.	Possible linkages between the inner and outer cellular states of human induced pluripotent stem cells.	BMC Syst Biol.	5 Suppl 1	S17	2011

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Tateno H, Toyota M, Saito S, Onuma Y, Ito Y, Hiemori K, Fukumura M, Matsushima A, Nakanishi M, Ohnuma K, Akutsu H, Umezawa A, Horimoto K, Hirabayashi J, Asashima M.	Glycome diagnosis of human induced pluripotent stem cells using lectin microarray.	J Biol Chem	286(23)	20345-30353	2011
Higuchi A, Ling QD, Ko YA, Chang Y, Umezawa A.	Biomaterials for the feeder-free culture of human embryonic stem cells and induced pluripotent stem cells.	Chem Rev.	111(5)	3021-3035	2011
Hasebe Y, Hasegawa S, Hashimoto N, Toyoda M, Matsumoto K, Umezawa A, Yagami A, Matsunaga K, Mizutani H, Nakata S, Akamatsu H.	Analysis of cell characterization using cell surface markers in the dermis.	J Dermatol Sci	62(2)	98-106	2011
Nishino K, Toyoda M, Yamazaki-Inoue M, Fukawatase Y, Chikazawa E, Sakaguchi H, Akutsu H, Umezawa A.	DNA methylation dynamics in human induced pluripotent stem cells over time.	PLoS Genet	7(5)	e1002085	2011
Sato B, Katagiri YU, Miyado K, Okino N, Ito M, Akutsu H, Okita H, Umezawa A, Fujimoto J, Toshimori K, Kiyokawa N.	Lipid rafts enriched in monosialylGb5Cer carrying the stage-specific embryonic antigen-4 epitope are involved in development of mouse preimplantation embryos at cleavage stage.	BMC Dev Biol	11	22	2011
Yazawa T, Kawabe S, Inaoka Y, Okada R, Mizutani T, Imamichi Y, Ju Y, Yamazaki Y, Usami Y, Kuribayashi M, Umezawa A, Miyamoto K.	Differentiation of mesenchymal stem cells and embryonic stem cells into steroidogenic cells using steroidogenic factor-1 and liver receptor homolog-1.	Mol Cell Endocrinol	336(1-2)	127-132	2011



発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Nishi M, Akutsu H, Masui S, Kondo A, Nagashima Y, Kimura H, Perrem K, Shigeri Y, Toyoda M, Okayama A, Hirano H, Umezawa A, Yamamoto N, Lee SW, Ryo A.	A distinct role for Pin1 in the induction and maintenance of pluripotency.	J Biol Chem	286(13)	11593-11603	2011
Sato T, Iso Y, Uyama T, Kawachi K, Wakabayashi K, Omori Y, Soda T, Shoji M, Koba S, Yokoyama S, Fukuda N, Saito S, Katagiri T, Kobayashi Y, Takeyama Y, Umezawa A, Suzuki H.	Coronary vein infusion of multipotent stromal cells from bone marrow preserves cardiac function in swine ischemic cardiomyopathy via enhanced neovascularization.	Lab Invest	91(4)	553-564	2011

# Efficient Generation of Functional Hepatocytes From Human Embryonic Stem Cells and Induced Pluripotent Stem Cells by HNF4 $\alpha$ Transduction

Kazuo Takayama<sup>1,2</sup>, Mitsuru Inamura<sup>1,2</sup>, Kenji Kawabata<sup>2,3</sup>, Kazufumi Katayama<sup>1</sup>, Maiko Higuchi<sup>2</sup>, Katsuhisa Tashiro<sup>2</sup>, Aki Nonaka<sup>2</sup>, Fuminori Sakurai<sup>1</sup>, Takao Hayakawa<sup>4,5</sup>, Miho Kusuda Furue<sup>6,7</sup> and Hiroyuki Mizuguchi<sup>1,2,8</sup>

<sup>1</sup>Laboratory of Biochemistry and Molecular Biology, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan; <sup>2</sup>Laboratory of Stem Cell Regulation, National Institute of Biomedical Innovation, Osaka, Japan; <sup>3</sup>Laboratory of Biomedical Innovation, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan; <sup>4</sup>Pharmaceuticals and Medical Devices Agency, Tokyo, Japan; <sup>5</sup>Pharmaceutical Research and Technology Institute, Kinki University, Osaka, Japan; <sup>6</sup>JCRB Cell Bank, Division of Bioresources, National Institute of Biomedical Innovation, Osaka, Japan; <sup>7</sup>Laboratory of Cell Processing, Institute for Frontier Medical Sciences, Kyoto University, Kyoto, Japan; <sup>8</sup>The Center for Advanced Medical Engineering and Informatics, Osaka University, Osaka, Japan

Hepatocyte-like cells from human embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) are expected to be a useful source of cells drug discovery. Although we recently reported that hepatic commitment is promoted by transduction of SOX17 and HEX into human ESC- and iPSC-derived cells, these hepatocyte-like cells were not sufficiently mature for drug screening. To promote hepatic maturation, we utilized transduction of the hepatocyte nuclear factor 4 $\alpha$  (HNF4 $\alpha$ ) gene, which is known as a master regulator of liver-specific gene expression. Adenovirus vector-mediated overexpression of HNF4 $\alpha$  in hepatoblasts induced by SOX17 and HEX transduction led to upregulation of epithelial and mature hepatic markers such as cytochrome P450 (CYP) enzymes, and promoted hepatic maturation by activating the mesenchymal-to-epithelial transition (MET). Thus HNF4 $\alpha$  might play an important role in the hepatic differentiation from human ESC-derived hepatoblasts by activating the MET. Furthermore, the hepatocyte like-cells could catalyze the toxication of several compounds. Our method would be a valuable tool for the efficient generation of functional hepatocytes derived from human ESCs and iPSCs, and the hepatocyte-like cells could be used for predicting drug toxicity.

Received 19 July 2011; accepted 28 September 2011; published online 8 November 2011. doi:10.1038/mt.2011.234

## INTRODUCTION

Human embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) are able to replicate indefinitely and differentiate into most of the body's cell types.<sup>1,2</sup> They could provide an unlimited source of cells for various applications. Hepatocyte-like cells, which are differentiated from human ESCs and iPSCs,

would be useful for basic research, regenerative medicine, and drug discovery.<sup>3</sup> In particular, it is expected that hepatocyte-like cells will be utilized as a tool for cytotoxicity screening in the early phase of pharmaceutical development. To catalyze the toxication of several compounds, hepatocyte-like cells need to be mature enough to exhibit hepatic functions, including high activity levels of the cytochrome P450 (CYP) enzymes. Because the present technology for the generation of hepatocyte-like cells from human ESCs and iPSCs, which is expected to be utilized for drug discovery, is not refined enough for this application, it is necessary to improve the efficiency of hepatic differentiation. Although conventional methods such as growth factor-mediated hepatic differentiation are useful to recapitulate liver development, they lead to only a heterogeneous hepatocyte population.<sup>4-6</sup> Recently, we showed that transcription factors are transiently transduced to promote hepatic differentiation in addition to the conventional differentiation method which uses only growth factors.<sup>7</sup> Ectopic expression of Sry-related HMG box 17 (SOX17) or hematopoietically expressed homeobox (HEX) by adenovirus (Ad) vectors in human ESC-derived mesendoderm or definitive endoderm (DE) cells markedly enhances the endoderm differentiation or hepatic commitment, respectively.<sup>7,8</sup> However, further hepatic maturation is required for drug screening.

The transcription factor hepatocyte nuclear factor 4 $\alpha$  (HNF4 $\alpha$ ) is initially expressed in the developing hepatic diverticulum on E8.75,<sup>9,10</sup> and its expression is elevated as the liver develops. A previous loss-of-function study showed that HNF4 $\alpha$  plays a critical role in liver development; conditional deletion of HNF4 $\alpha$  in fetal hepatocytes results in the faint expression of many mature hepatic enzymes and the impairment of normal liver morphology.<sup>11</sup> The genome-scale chromatin immunoprecipitation assay showed that HNF4 $\alpha$  binds to the promoters of nearly half of the genes expressed in the mouse liver,<sup>12</sup> including cell adhesion and junctional proteins,<sup>13</sup> which are important in

**Correspondence:** Hiroyuki Mizuguchi, Laboratory of Biochemistry and Molecular Biology, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan. E-mail: mizuguch@phs.osaka-u.ac.jp


the hepatocyte epithelial structure.<sup>14</sup> In addition, HNF4 $\alpha$  plays a critical role in hepatic differentiation and in a wide variety of liver functions, including lipid and glucose metabolism.<sup>15,16</sup> Although HNF4 $\alpha$  could promote transdifferentiation into hepatic lineage from hematopoietic cells,<sup>17</sup> the function of HNF4 $\alpha$  in hepatic differentiation from human ESCs and iPSCs remains unknown. A previous study showed that hepatic differentiation from mouse hepatic progenitor cells is promoted by HNF4 $\alpha$ , although many of the hepatic markers that they examined were target genes of HNF4 $\alpha$ .<sup>18</sup> They transplanted the HNF4 $\alpha$ -overexpressed mouse hepatic progenitor cells to promote hepatic differentiation, but they did not examine the markers that relate to hepatic maturation such as CYP enzymes, conjugating enzymes, and hepatic transporters.

In this study, we examined the role of HNF4 $\alpha$  in hepatic differentiation from human ESCs and iPSCs. The human ESC- and iPSC-derived hepatoblasts, which were efficiently generated by sequential transduction of SOX17 and HEX, were transduced with HNF4 $\alpha$ -expressing Ad vector (Ad-HNF4 $\alpha$ ), and then the expression of hepatic markers of the hepatocyte-like cells were assessed. In addition, we examined whether or not the hepatocyte-like cells, which were generated by sequential transduction of SOX17, HEX, and HNF4 $\alpha$ , were able to predict the toxicity of several compounds.

## RESULTS

### Stage-specific HNF4 $\alpha$ transduction in hepatoblasts selectively promotes hepatic differentiation

The transcription factor HNF4 $\alpha$  plays an important role in both liver generation<sup>11</sup> and hepatic differentiation from human ESCs and iPSCs (**Supplementary Figure S1**). We expected that hepatic differentiation could be accelerated by HNF4 $\alpha$  transduction. To examine the effect of forced expression of HNF4 $\alpha$  in the hepatic differentiation from human ESC- and iPSC-derived cells, we used a fiber-modified Ad vector.<sup>19</sup> Initially, we optimized the time period for Ad-HNF4 $\alpha$  transduction. Human ESC (H9)-derived DE cells (day 6) (**Supplementary Figures S2 and S3a**), hepatoblasts (day 9) (**Supplementary Figures S2 and S3b**), or a heterogeneous population consisting of hepatoblasts, hepatocytes, and cholangiocytes (day 12) (**Supplementary Figures S2 and S3c**) were transduced with Ad-HNF4 $\alpha$  and then the Ad-HNF4 $\alpha$ -transduced cells were cultured until day 20 of differentiation (**Figure 1**). We ascertained the expression of exogenous HNF4 $\alpha$  in human ESC-derived hepatoblasts (day 9) transduced with Ad-HNF4 $\alpha$  (**Supplementary Figure S4**). The transduction of Ad-HNF4 $\alpha$  into human ESC-derived hepatoblasts (day 9) led to the highest expression levels of the hepatocyte markers *albumin* (*ALB*)<sup>20</sup> and  *$\alpha$ -1-antitrypsin* (**Figure 1a**). In contrast, the expression levels of the cholangiocyte markers *cytokeratin 7* (*CK7*)<sup>21</sup> and *SOX9*<sup>22</sup> were




**Figure 1** Transduction of HNF4 $\alpha$  into hepatoblasts promotes hepatic differentiation. (**a–c**) The human ESC (H9)-derived cells, which were cultured for 6, 9, or 12 days according to the protocol described in **Figure 2a**, were transduced with 3,000 vector particles (VP)/cell of Ad-HNF4 $\alpha$  for 1.5 hours and cultured until day 20. The gene expression levels of (**a**) hepatocyte markers (*ALB* and  *$\alpha$ -1-antitrypsin*), (**b**) cholangiocyte markers (*CK7* and *SOX9*), and (**c**) pancreas markers (*PDX1* and *NKX2.2*) were examined by real-time RT-PCR on day 0 (human ESCs (hESCs)) or day 20 of differentiation. The horizontal axis represents the days when the cells were transduced with Ad-HNF4 $\alpha$ . On the y-axis, the level of the cells without Ad-HNF4 $\alpha$  transduction on day 20 was taken as 1.0. All data are represented as means  $\pm$  SD ( $n = 3$ ). ESC, embryonic stem cell; HNF4 $\alpha$ , hepatocyte nuclear factor 4 $\alpha$ ; RT-PCR, reverse transcription-PCR.


downregulated in the cells transduced on day 9 as compared with nontransduced cells (Figure 1b). This might be because hepatic differentiation was selectively promoted and biliary differentiation was repressed by the transduction of HNF4 $\alpha$  in hepatoblasts. The expression levels of the pancreas markers *PDX1*<sup>23</sup> and *NKX2.2*<sup>24</sup> did not make any change in the cells transduced on day 9 as compared with nontransduced cells (Figure 1c). Interestingly, the expression levels of the pancreas markers were upregulated, when Ad-HNF4 $\alpha$  transduction was performed into DE cells (day 6) (Figure 1c). These results suggest that HNF4 $\alpha$  might promote not only hepatic differentiation but also pancreatic differentiation, although the optimal stage of HNF4 transduction for the differentiation of each cell is different. We have confirmed that there was no difference between nontransduced cells and Ad-LacZ-transduced cells in the gene expression levels of all the markers investigated in Figure 1a–c (data not shown). We also confirmed that Ad vector-mediated gene expression in the human ESC-derived hepatoblasts (day 9) continued until day 14 and almost disappeared on day 18 (Supplementary Figure S5). These results indicated that the stage-specific HNF4 $\alpha$  overexpression in human ESC-derived hepatoblasts (day 9) was essential for promoting efficient hepatic differentiation.

### Transduction of HNF4 $\alpha$ into human ESC- and iPSC-derived hepatoblasts efficiently promotes hepatic maturation

From the results of Figure 1, we decided to transduce hepatoblasts (day 9) with Ad-HNF4 $\alpha$ . To determine whether hepatic maturation is promoted by Ad-HNF4 $\alpha$  transduction, Ad-HNF4 $\alpha$ -transduced cells were cultured until day 20 of differentiation according to the schematic protocol described in Figure 2a. After the hepatic maturation, the morphology of human ESCs was gradually changed into that of hepatocytes: polygonal with distinct round nuclei (day 20) (Figure 2b). Interestingly, a portion of the hepatocyte-like cells, which were ALB<sup>20</sup>-, CK18<sup>21</sup>-, CYP2D6-, and CYP3A4<sup>25</sup>-positive cells, had double nuclei, which was also observed in primary human hepatocytes (Figure 2b,c, and Supplementary Figure S6). We also examined the hepatic gene expression levels on day 20 of differentiation (Figure 3a,b). The gene expression analysis of *CYP1A2*, *CYP2C9*, *CYP2C19*, *CYP2D6*, *CYP3A4*, and *CYP7A1*<sup>25</sup> showed higher expression levels in all of Ad-SOX17-, Ad-HEX-, and Ad-HNF4 $\alpha$ -transduced cells (three factors-transduced cells) as compared with those in both Ad-SOX17- and Ad-HEX-transduced cells (two factors-transduced cells) on day 20 (Figure 3a). The gene expression level of NADPH-CYP reductase



**Figure 2** Hepatic differentiation of human ESCs and iPSCs transduced with three factors. **(a)** The procedure for differentiation of human ESCs and iPSCs into hepatocytes via DE cells and hepatoblasts is presented schematically. The hESF-DIF medium was supplemented with 10  $\mu$ g/ml human recombinant insulin, 5  $\mu$ g/ml human apotransferrin, 10  $\mu$ mol/l 2-mercaptoethanol, 10  $\mu$ mol/l ethanolamine, 10  $\mu$ mol/l sodium selenite, and 0.5 mg/ml fatty-acid-free BSA. The L15 medium was supplemented with 8.3% tryptose phosphate broth, 8.3% FBS, 10  $\mu$ mol/l hydrocortisone 21-hemisuccinate, 1  $\mu$ mol/l insulin, and 25 mmol/l NaHCO<sub>3</sub>. **(b)** Sequential morphological changes (day 0–20) of human ESCs (H9) differentiated into hepatocytes via DE cells and hepatoblasts are shown. Red arrow shows the cells that have double nuclei. **(c)** The morphology of primary human hepatocytes is shown. Bar represents 50  $\mu$ m. BSA, bovine serum albumin; DE, definitive endoderm; ESC, embryonic stem cell; iPSC, induced pluripotent stem cell.



**Figure 3** Transduction of HNF4 $\alpha$  promotes hepatic maturation from human ESCs and iPSCs. **(a,b)** The human ESCs were differentiated into hepatocytes according to the protocol described in **Figure 2a**. On day 20 of differentiation, the gene expression levels of **(a)** CYP enzymes (*CYP1A2*, *CYP2C9*, *CYP2C19*, *CYP2D6*, *CYP3A4*, and *CYP7A1*) and **(b)** *POR* were examined by real-time RT-PCR in undifferentiated human ESCs (hESCs), the hepatocyte-like cells, and primary human hepatocytes (PH, hatched bar). On the y-axis, the expression level of primary human hepatocytes, which were cultured for 48 hours after the cells were plated, was taken as 1.0. **(c–e)** The hepatocyte-like cells (day 20) were subjected to immunostaining with **(c)** anti-drug-metabolizing enzymes (*CYP2D6*, *CYP3A4*, and *CYP7A1*), **(d)** anti-hepatic surface protein (*ASGR1* and *c-Met*), and **(e)** anti-ALB antibodies, and then the percentage of antigen-positive cells was examined by flow cytometry on day 20 of differentiation. All data are represented as means  $\pm$  SD ( $n = 3$ ). ESC, embryonic stem cell; HNF4 $\alpha$ , hepatocyte nuclear factor 4 $\alpha$ ; iPSC, induced pluripotent stem cell.

(*POR*)<sup>26</sup>, which is required for the normal function of CYPs, was also higher in the three factors-transduced cells (**Figure 3b**). The gene expression analysis of ALB,  $\alpha$ -1-antitrypsin ( $\alpha$ -1-AT), transthyretin, hepatic conjugating enzymes, hepatic transporters, and hepatic transcription factors also showed higher expression levels in the three factors-transduced cells (**Supplementary Figures S7 and S8**). Moreover, the gene expression levels of these hepatic markers of three factor-transduced cells were similar to those of primary human hepatocytes, although the levels depended on the type of gene (**Figure 3a,b**, and **Supplementary Figures S7 and S8**). To confirm that similar results could be obtained with human iPSCs, we used three human iPSC cell lines (201B7, Dotcom, and Tic). The gene expression of hepatic markers in human ESC- and iPSC-derived hepatocytes were analyzed by real-time reverse transcription-PCR on day 20 of differentiation. Three human iPSC cell lines as well as human ESCs also effectively differentiated into hepatocytes in response to transduction of the three factors

(**Supplementary Figure S9**). Interestingly, we observed differences in the hepatic maturation efficiency among the three human iPSC cell lines. That is, two of the human iPSC cell lines (Tic and Dotcom) were more committed to the hepatic lineage than another human iPSC cell line (201B7). Because almost homogeneous hepatocyte-like cells would be more useful in basic research, regenerative medicine, and drug discovery, we also examined whether our novel methods for hepatic maturation could generate a homogeneous hepatocyte population by flow cytometry analysis (**Figure 3c–e**). The percentages of CYP2D6-, CYP3A4-, and CYP7A1-positive cells were ~80% in the three factors-transduced cells, while they were ~50% in the two factors-transduced cells (**Figure 3c**). The percentages of hepatic surface antigen (asialoglycoprotein receptor 1 (*ASGR1*) and met proto-oncogene (*c-Met*))-positive cells (**Figure 3d**) and ALB-positive cells (**Figure 3e**) were also ~80% in the three factors-transduced cells. These results indicated that a nearly homogeneous population was obtained by our differentiation protocol

using the transduction of three functional genes (SOX17, HEX, and HNF4 $\alpha$ ).

### The three factors-transduced cells have characteristics of functional hepatocytes

The hepatic functions of the hepatocyte-like cells, such as the uptake of low-density lipoprotein (LDL) and CYP enzymes activity, of the hepatocyte-like cells were examined on day 20 of differentiation. Approximately 87% of the three factors-transduced cells uptook LDL in the medium, whereas only 44% of the two factors-transduced cells did so (Figure 4a). The activities of CYP enzymes of the hepatocyte-like cells were measured according to the metabolism of the CYP3A4, CYP2C9, or CYP1A2 substrates (Figure 4b). The metabolites were detected in the three factors-transduced cells and their activities were higher than those of the two factors-transduced cells (dimethyl sulfoxide (DMSO) column). We further tested the induction of CYP3A4, CYP2C9, and CYP1A2 by chemical stimulation, since CYP3A4, CYP2C9, and CYP1A2 are the important prevalent CYP isozymes in the liver and are involved in the metabolism of a significant proportion of the currently available commercial drugs (rifampicin or omeprazole column). It is well known that CYP3A4 and CYP2C9 can be induced by rifampicin, whereas CYP1A2 can be induced by omeprazole. The hepatocyte-like cells were treated with either of these. Although undifferentiated human ESCs responded to neither rifampicin nor omeprazole (data not shown), the hepatocyte-like cells produced more metabolites in response to chemical stimulation as well as primary hepatocytes (Figure 4b). The activity levels of the hepatocyte-like cells as compared with those of primary human hepatocytes depended on the types of CYP; the CYP3A4 activity of the hepatocyte-like cells was similar to that of primary human hepatocytes, whereas the CYP2C9 and CYP1A2 activities of the hepatocyte-like cells were slightly lower than those of primary human hepatocytes (Figure 3a). These results indicated that high levels of functional CYP enzymes were detectable in the hepatocyte-like cells.


The metabolism of diverse compounds involving uptake, conjugation, and the subsequent release of the compounds is an important function of hepatocytes. Uptake and release of Indocyanine green (ICG) can often be used to identify hepatocytes in ESC differentiation models.<sup>27</sup> To investigate this function in our hepatocyte-like cells, we compared this ability of the three factors-transduced cells with that of the two factors-transduced cells on day 20 of differentiation (Figure 4c). The three factors-transduced cells had more ability to uptake ICG and to excrete ICG by culturing without ICG for 6 hours. We also examined whether the hepatocyte-like cells could store glycogen, a characteristic of functional hepatocytes (Figure 4d). On day 20 of differentiation, the three factors-transduced cells and the two factors-transduced cells were stained for cytoplasmic glycogen using the Periodic Acid-Schiff staining procedure. The three factors-transduced cells exhibited more abundant storage of glycogen than the two-factors-transduced cells. These results showed that abundant hepatic functions, such as uptake and excretion of ICG and storage of glycogen, were obtained by the transduction of three factors.

Many adverse drug reactions are caused by the CYP-dependent activation of drugs into reactive metabolites.<sup>28</sup> In order to examine


metabolism-mediated toxicity and to improve the safety of drug candidates, primary human hepatocytes are widely used.<sup>28</sup> Because primary human hepatocytes have quite different characteristics among distinct lots and because it is difficult to purchase large amounts of primary human hepatocytes that have the same characteristics, hepatocyte-like cells are expected to be used for this purpose. To examine whether our hepatocyte-like cells could be used to predict metabolism-mediated toxicity, the hepatocyte-like cells were incubated with four substrates (troglitazone, acetaminophen, cyclophosphamide, and carbamazepine), which are known to generate toxic metabolites by CYP enzymes, and then the cell viability was measured (Figure 4e). The cell viability of the two factors plus Ad-LacZ-transduced cells were higher than that of the three factors-transduced cells at each different concentration of four test compounds. These results indicated that the three factors-transduced cells could more efficiently metabolize the test compounds and thereby induce higher toxicity than either the two factors-transduced cells or undifferentiated human ESCs. The cell viability of the three factors-transduced cells was slightly higher than that of primary human hepatocytes.

### HNF4 $\alpha$ promotes hepatic maturation by activating mesenchymal-to-epithelial transition

HNF4 $\alpha$  is known as a dominant regulator of the epithelial phenotype because its ectopic expression in fibroblasts (such as NIH 3T3 cells) induces mesenchymal-to-epithelial transition (MET)<sup>11</sup>, although it is not known whether HNF4 $\alpha$  can promote MET in hepatic differentiation. Therefore, we examined whether HNF4 $\alpha$  transduction promotes hepatic maturation from hepatoblasts by activating MET. To clarify whether MET is activated by HNF4 $\alpha$  transduction, the human ESC-derived hepatoblasts (day 9) were transduced with Ad-LacZ or Ad-HNF4 $\alpha$ , and the resulting phenotype was analyzed on day 12 of differentiation (Figure 5). This time, we confirmed that HNF4 $\alpha$  transduction decreased the population of N-cadherin (hepatoblast marker)-positive cells,<sup>29</sup> whereas it increased that of ALB (hepatocyte marker)-positive cells (Figure 5a). The number of CK7 (cholangiocyte marker)-positive population did not change (Figure 5a). To investigate whether these results were attributable to MET, the alteration of the expression of several mesenchymal and epithelial markers was examined (Figure 5b). The human ESC-derived hepatoblasts (day 9) were almost homogeneously N-cadherin<sup>30</sup> (mesenchymal marker)-positive and E-cadherin<sup>11</sup> (epithelial marker)-negative, demonstrating that human ESC-derived hepatoblasts have mesenchymal characteristics (Figure 5a,b). After HNF4 $\alpha$  transduction, the number of E-cadherin-positive cells was increased and reached ~90% on day 20, whereas that of N-cadherin-positive cells was decreased and was less than 5% on day 20 (Supplementary Figure S10). These results indicated that MET was promoted by HNF4 $\alpha$  transduction in hepatic differentiation from hepatoblasts. Interestingly, the number of growing cells was decreased by HNF4 $\alpha$  transduction (Figure 5c), and the cell growth was delayed by HNF4 $\alpha$  transduction (Supplementary Figure S11). This decrease in the number of growing cells might have been because the differentiation was promoted by HNF4 $\alpha$  transduction. We also confirmed that MET was promoted by HNF4 $\alpha$  transduction in the gene expression levels (Figure 5d).



**Figure 4** Transduction of the three factors enhances hepatic functions. The human ESCs were differentiated into hepatoblasts and transduced with 3,000 VP/cell of Ad-LacZ or Ad-HNF4 $\alpha$  for 1.5 hours and cultured until day 20 of differentiation according to the protocol described in **Figure 2a**. The hepatic functions of the two factors plus Ad-LacZ-transduced cells (SOX17+HEX+LacZ) and the three factors-transduced cells (SOX17+HEX+HNF4 $\alpha$ ) were compared. **(a)** Undifferentiated human ESCs (hESCs) and the hepatocyte-like cells (day 20) were cultured with medium containing Alexa-Fluor 488-labeled LDL (green) for 1 hour, and immunohistochemistry and flow cytometry analysis were performed. The percentage of LDL-positive cells was measured by flow cytometry. Nuclei were counterstained with DAPI (blue). The bar represents 100  $\mu$ m. **(b)** Induction of CYP3A4 (left), CYP2C9 (middle), or CYP1A2 (right) by DMSO (gray bar), rifampicin (black bar), or omeprazole (black bar) in the hepatocyte-like cells (day 20) and primary human hepatocytes (PH), which were cultured for 48 hours after the cells were plated. On the y-axis, the activity of primary human hepatocytes that have been cultured with medium containing DMSO was taken as 1.0. **(c)** The hepatocyte-like cells (day 20) (upper column) were examined for their ability to take up Indocyanin Green (ICG) and release it 6 hours thereafter (lower column). **(d)** Glycogen storage of the hepatocyte-like cells (day 20) was assessed by Periodic Acid-Schiff (PAS) staining. PAS staining was performed on day 20 of differentiation. Glycogen storage is indicated by pink or dark red-purple cytoplasm. The bar represents 100  $\mu$ m. **(e)** The cell viability of undifferentiated human ESCs (black), two factors plus Ad-LacZ-transduced cells (green), the three factors-transduced cells (blue), and primary human hepatocytes (red) was assessed by Alamar Blue assay after 48 hours exposure to different concentrations of four test compounds (troglitazone, acetaminophen, cyclophosphamide, and carbamazepine). The cell viability is expressed as a percentage of cells treated with solvent only treat: 0.1% DMSO except for carbamazepine: 0.5% DMSO. All data are represented as means  $\pm$  SD ( $n = 3$ ). ESC, embryonic stem cell; DMSO, dimethyl sulfoxide; LDL, low-density lipoprotein.



**Figure 5** HNF4 $\alpha$  promotes hepatic differentiation by activating MET. Human ESCs were differentiated into hepatoblasts according to the protocol described in **Figure 2a**, and then transduced with 3,000 VP/cell of Ad-LacZ or Ad-HNF4 $\alpha$  for 1.5 hours, and finally cultured until day 12 of differentiation. **(a)** The hepatoblasts, two factors plus Ad-LacZ-transduced cells (SOX17+HEX+LacZ) (day 12), and the three factors-transduced cells (SOX17+HEX+HNF4 $\alpha$ ) (day 12) were subjected to immunostaining with anti-N-cadherin, ALB, or CK7 antibodies. The percentage of antigen-positive cells was measured by flow cytometry. **(b)** The cells were subjected to immunostaining with anti-N-cadherin (green), E-cadherin (green), or HNF4 $\alpha$  (red) antibodies on day 9 or day 12 of differentiation. Nuclei were counterstained with DAPI (blue). The bar represents 50  $\mu$ m. Similar results were obtained in two independent experiments. **(c)** The cell cycle was examined on day 9 or day 12 of differentiation. The cells were stained with Pyronin Y (y-axis) and Hoechst 33342 (x-axis) and then analyzed by flow cytometry. The growth fraction of cells is the population of actively dividing cells (G1/S/G2/M). **(d)** The expression levels of *AFP*, *PROX1*,  $\alpha$ -1-antitrypsin, *ALB*, *CK7*, *SOX9*, *N-cadherin*, *Snail1*, *Ceacam1*, *E-cadherin*, *p15*, and *p21* were examined by real-time RT-PCR on day 9 or day 12 of differentiation. The expression level of hepatoblasts (day 9) was taken as 1.0. All data are represented as means  $\pm$  SD ( $n = 3$ ). **(e)** The model of efficient hepatic differentiation from human ESCs and iPSCs in this study is summarized. The human ESCs and iPSCs differentiate into hepatocytes via definitive endoderm and hepatoblasts. At each stage, the differentiation is promoted by stage-specific transduction of appropriate functional genes. In the last stage of hepatic differentiation, HNF4 $\alpha$  transduction provokes hepatic maturation by activating MET. ESC, embryonic stem cell; HNF4 $\alpha$ , hepatocyte nuclear factor 4 $\alpha$ ; iPSC, induced pluripotent stem cell; MET, mesenchymal-to-epithelial transition; RT-PCR, reverse transcription-PCR; VP, vector particle.

The gene expression levels of hepatocyte markers ( $\alpha$ -1-antitrypsin and *ALB*)<sup>20</sup> and epithelial markers (*Ceacam1* and *E-cadherin*) were upregulated by HNF4 $\alpha$  transduction. On the other hand, the gene expression levels of hepatoblast markers (*AFP* and *PROX1*)<sup>31</sup>, mesenchymal markers (*N-cadherin* and *Snail*)<sup>32</sup>, and cyclin dependent kinase inhibitor (*p15* and *p21*)<sup>33</sup> were downregulated by HNF4 $\alpha$  transduction. HNF4 $\alpha$  transduction did not change the expression levels of cholangiocyte markers (*CK7* and *SOX9*). We conclude that HNF4 $\alpha$  promotes hepatic maturation by activating MET.

## DISCUSSION

This study has two main purposes: the generation of functional hepatocytes from human ESCs and iPSCs for application to drug toxicity screening in the early phase of pharmaceutical development

and; elucidation of the HNF4 $\alpha$  function in hepatic maturation from human ESCs. We initially confirmed the importance of transcription factor HNF4 $\alpha$  in hepatic differentiation from human ESCs by using a published data set of gene array analysis (**Supplementary Figure S1**).<sup>34</sup> We speculated that HNF4 $\alpha$  transduction could enhance hepatic differentiation from human ESCs and iPSCs.

To generate functional hepatocytes from human ESCs and iPSCs and to elucidate the function of HNF4 $\alpha$  in hepatic differentiation from human ESCs, we examined the stage-specific roles of HNF4 $\alpha$ . We found that hepatoblast (day 9) stage-specific HNF4 $\alpha$  transduction promoted hepatic differentiation (**Figure 1**). Because endogenous HNF4 $\alpha$  is initially expressed in the hepatoblast,<sup>9,10</sup> our system might adequately reflect early embryogenesis. However, HNF4 $\alpha$  transduction at an inappropriate stage (day 6 or day 12) promoted



bidirectional differentiation; heterogeneous populations, which contain the hepatocytes and pancreas cells or hepatocytes and cholangiocytes, were obtained, respectively (Figure 1), consistent with a previous report that HNF4 $\alpha$  plays an important role not only in the liver but also in the pancreas.<sup>12</sup> Therefore, we concluded that HNF4 $\alpha$  plays a significant stage-specific role in the differentiation of human ESC- and iPSC-derived hepatoblasts to hepatocytes (Figure 5e).

We found that the expression levels of the hepatic functional genes were upregulated by HNF4 $\alpha$  transduction (Figure 3a,b, and Supplementary Figures S7 and S8). Although the c/EBP $\alpha$  and GATA4 expression levels of the three factors-transduced cells were higher than those of primary human hepatocytes, the FOXA1, FOXA2, FOXA3, and HNF1 $\alpha$ , which are known to be important for hepatic direct reprogramming and hepatic differentiation,<sup>35,36</sup> expression levels of three factors-transduced cells were slightly lower than those of primary human hepatocytes (Supplementary Figure S8). Therefore, additional transduction of FOXA1, FOXA2, FOXA3, and HNF1 $\alpha$  might promote further hepatic maturation. Some previous hepatic differentiation protocols that utilized growth factors without gene transfer led to the appearance only of heterogeneous hepatocyte populations.<sup>4-6</sup> The HNF4 $\alpha$  transduction led not only to the upregulation of expression levels of several hepatic markers but also to an almost homogeneous hepatocyte population; the differentiation efficacy based on CYPs, ASGR1, or ALB expression was ~80% (Figure 3c-e). The efficient hepatic maturation in this study might be attributable to the activation of many hepatocyte-associated genes by the transduction of HNF4 $\alpha$ , which binds to the promoters of nearly half of the genes expressed in the liver.<sup>12</sup> In the later stage of hepatic maturation, hepatocyte-associated genes would be strongly upregulated by endogenous transcription factors but not exogenous HNF4 $\alpha$  because transgene expression by Ad vectors was almost disappeared on day 18 (Supplementary Figure S5). Another reason for the efficient hepatic maturation would be that sequential transduction of SOX17, HEX, and HNF4 $\alpha$  could mimic hepatic differentiation in early embryogenesis.

Next, we examined whether or not the hepatocyte-like cells had hepatic functions. The activity of many kinds of CYPs was upregulated by HNF4 $\alpha$  transduction (Figure 4b). Ad-HNF4 $\alpha$ -transduced cells exhibit many characteristics of hepatocytes: uptake of LDL, uptake and excretion of ICG, and storage of glycogen (Figure 4a,c,d). Many conventional tests of hepatic characteristics have shown that the hepatocyte-like cells have mature hepatocyte functions. Furthermore, the hepatocyte-like cells can catalyze the toxication of several compounds (Figure 4e). Although the activities to catalyze the toxication of test compounds in primary human hepatocytes are slightly higher than those in the hepatocyte-like cells, the handling of primary human hepatocytes is difficult for a number of reasons: since their source is limited, large-scale primary human hepatocytes are difficult to prepare as a homogeneous population. Therefore, the hepatocyte-like cells derived from human ESCs and iPSCs would be a valuable tool for predicting drug toxicity. To utilize the hepatocyte-like cells in a drug toxicity study, further investigation of the drug metabolism capacity and CYP induction potency will be needed.

We also investigated the mechanisms underlying efficient hepatic maturation by HNF4 $\alpha$  transduction. Although the

number of cholangiocyte populations did not change by HNF4 $\alpha$  transduction, we found that the number of hepatoblast populations decreased and that of hepatocyte populations increased, indicating that HNF4 $\alpha$  promotes selective hepatic differentiation from hepatoblasts (Figure 5a). As previously reported, HNF4 $\alpha$  regulates the expression of a broad range of genes that code for cell adhesion molecules,<sup>13</sup> extracellular matrix components, and cytoskeletal proteins, which determine the main morphological characteristics of epithelial cells.<sup>14,35,37</sup> In this study, we elucidated that MET was promoted by HNF4 $\alpha$  transduction (Figure 5b,d). Thus, we conclude that HNF4 $\alpha$  overexpression in hepatoblasts promotes hepatic differentiation by activating MET (Figure 5e).

Using human iPSCs as well as human ESCs, we confirmed that the stage-specific overexpression of HNF4 $\alpha$  could promote hepatic maturation (Supplementary Figure S9). Interestingly, the differentiation efficacies differed among human iPSC cell lines: two of the human iPSC cell lines (Dotcom and Tic) were more committed to the hepatic lineage than another human iPSC cell line (201B7) (Supplementary Figure S7). Therefore, it would be necessary to select a human iPSC cell line that is suitable for hepatic maturation in the case of medical applications, such as drug screening and liver transplantation. The difference of hepatic differentiation efficacy among the three iPSC lines might be due to the difference of epigenetic memory of original cells or the difference of the inserted position of the foreign genes for the reprogramming.

To control hepatic differentiation mimicking embryogenesis, we employed Ad vectors, which are one of the most efficient transient gene delivery vehicles and have been widely used in both experimental studies and clinical trials.<sup>38</sup> We used a fiber-modified Ad vector containing the EF-1 $\alpha$  promoter and a stretch of lysine residue (KKKKKKK, K7) peptides in the C-terminal region of the fiber knob.<sup>19</sup> The K7 peptide targets heparan sulfates on the cellular surface, and the fiber-modified Ad vector containing the K7 peptides was shown to be efficient for transduction into many kinds of cells including human ESCs and human ESC-derived cells.<sup>7-8,19</sup> Thus, Ad vector-mediated transient gene transfer should be a powerful tool for regulating cellular differentiation.

In summary, the findings described here demonstrate that transcription factor HNF4 $\alpha$  plays a crucial role in the hepatic differentiation from human ESC-derived hepatoblasts by activating MET (Figure 5e). In the present study, both human ESCs and iPSCs (three lines) were used and all cell lines showed efficient hepatic maturation, indicating that our protocol would be a universal tool for cell line-independent differentiation into functional hepatocytes. Moreover, the hepatocyte-like cells can catalyze the toxication of several compounds as primary human hepatocytes. Therefore, our technology, by sequential transduction of SOX17, HEX, and HNF4 $\alpha$ , would be a valuable tool for the efficient generation of functional hepatocytes derived from human ESCs and iPSCs, and the hepatocyte-like cells could be used for the prediction of drug toxicity.

## MATERIALS AND METHODS

**Human ESC and iPSC culture.** A human ES cell line, H9 (WiCell Research Institute, Madison, HI), was maintained on a feeder layer of mitomycin C-treated mouse embryonic fibroblasts (Millipore, Billerica, MA) with Repro Stem (Repro CELL, Tokyo, Japan) supplemented with 5ng/ml fibroblast

growth factor 2 (FGF2) (Sigma, St Louis, MO). Human ESCs were dissociated with 0.1 mg/ml dispase (Roche Diagnostics, Indianapolis, IN) into small clumps and then were subcultured every 4 or 5 days. H9 was used following the Guidelines for Derivation and Utilization of Human Embryonic Stem Cells of the Ministry of Education, Culture, Sports, Science and Technology of Japan. Two human iPS cell lines generated from the human embryonic lung fibroblast cell line MCR5 were provided from the JCRB Cell Bank (Tic, JCRB Number: JCRB1331; and Dotcom, JCRB Number: JCRB1327).<sup>39,40</sup> These human iPS cell lines were maintained on a feeder layer of mitomycin C-treated mouse embryonic fibroblasts with iPSELLON (Cardio, Kobe, Japan) supplemented with 10 ng/ml FGF2. Another human iPS cell line, 201B7, generated from human dermal fibroblasts was kindly provided by Dr S. Yamanaka (Kyoto University).<sup>2</sup> The human iPS cell line 201B7 was maintained on a feeder layer of mitomycin C-treated mouse embryonic fibroblasts with Repro Stem (Repro CELL) supplemented with 5 ng/ml FGF2 (Sigma). Human iPSCs were dissociated with 0.1 mg/ml dispase (Roche Diagnostics) into small clumps and were then subcultured every 5 or 6 days.

**In vitro differentiation.** Before the initiation of cellular differentiation, the medium of human ESCs and iPSCs was exchanged for a defined serum-free medium, hESF9, and cultured as we previously reported.<sup>41</sup> hESF9 consists of hESF-GRO medium (Cell Science & Technology Institute, Sendai, Japan) supplemented with 10  $\mu$ g/ml human recombinant insulin, 5  $\mu$ g/ml human apotransferrin, 10  $\mu$ mol/l 2-mercaptoethanol, 10  $\mu$ mol/l ethanolamine, 10  $\mu$ mol/l sodium selenite, oleic acid conjugated with fatty-acid-free bovine albumin (BSA), 10 ng/ml FGF2, and 100 ng/ml heparin (all from Sigma).

The differentiation protocol for the induction of DE cells, hepatoblasts, and hepatocytes was based on our previous report with some modifications.<sup>7</sup> Briefly, in mesendoderm differentiation, human ESCs and iPSCs were dissociated into single cells and cultured for 3 days on Matrigel (Becton, Dickinson and Company, Tokyo, Japan) in hESF-DIF medium (Cell Science & Technology Institute) supplemented with 10  $\mu$ g/ml human recombinant insulin, 5  $\mu$ g/ml human apotransferrin, 10  $\mu$ mol/l 2-mercaptoethanol, 10  $\mu$ mol/l ethanolamine, 10  $\mu$ mol/l sodium selenite, 0.5 mg/ml BSA, and 100 ng/ml Activin A (R&D Systems, Minneapolis, MN). To generate mesendoderm cells and DE cells, human ESC-derived cells were transduced with 3,000 vector particles (VP)/cell of Ad-SOX17 for 1.5 hours on day 3 and cultured until day 6 on Matrigel (BD) in hESF-DIF medium (Cell Science & Technology Institute) supplemented with 10  $\mu$ g/ml human recombinant insulin, 5  $\mu$ g/ml human apotransferrin, 10  $\mu$ mol/l 2-mercaptoethanol, 10  $\mu$ mol/l ethanolamine, 10  $\mu$ mol/l sodium selenite, 0.5 mg/ml BSA, and 100 ng/ml Activin A (R&D Systems). For induction of hepatoblasts, the DE cells were transduced with 3,000 VP/cell of Ad-HEX for 1.5 hours on day 6 and cultured for 3 days on a Matrigel (BD) in hESF-DIF (Cell Science & Technology Institute) medium supplemented with the 10  $\mu$ g/ml human recombinant insulin, 5  $\mu$ g/ml human apotransferrin, 10  $\mu$ mol/l 2-mercaptoethanol, 10  $\mu$ mol/l ethanolamine, 10  $\mu$ mol/l sodium selenite, 0.5 mg/ml BSA, 20 ng/ml bone morphogenetic protein 4 (R&D Systems), and 20 ng/ml FGF4 (R&D Systems). In hepatic differentiation, hepatoblasts were transduced with 3,000 VP/cell of Ad-LacZ or Ad-HNF4 $\alpha$  for 1.5 hr on day 9 and were cultured for 11 days on Matrigel (BD) in L15 medium (Invitrogen, Carlsbad, CA) supplemented with 8.3% tryptose phosphate broth (BD), 8.3% fetal bovine serum (Vita, Chiba, Japan), 10  $\mu$ mol/l hydrocortisone 21-hemisuccinate (Sigma), 1  $\mu$ mol/l insulin, 25 mmol/l NaHCO<sub>3</sub> (Wako, Osaka, Japan), 20 ng/ml hepatocyte growth factor (R&D Systems), 20 ng/ml Oncostatin M (R&D Systems), and 10<sup>-6</sup> mol/l Dexamethasone (Sigma).

**Ad vectors.** Ad vectors were constructed by an improved *in vitro* ligation method.<sup>42,43</sup> The human HNF4 $\alpha$  gene (accession number NM\_000457) was amplified by PCR using primers designed to incorporate the 5' Not I and 3' Xba I restriction enzyme sites: Fwd 5'-ggcctctagatggaggcaggagaatg-3' and Rev 5'-ccccgcggccgcagcgcttctagataac-3'. The human HNF4 $\alpha$  gene was inserted into pBSKII (Invitrogen), resulting in pBSKII-HNF4 $\alpha$ , and

then the human HNF4 $\alpha$  gene was inserted into pHMEF5,<sup>44</sup> which contains the human elongation factor-1 $\alpha$  (EF-1 $\alpha$ ) promoter, resulting in pHMEF-HNF4 $\alpha$ . The pHMEF-HNF4 $\alpha$  was digested with I-CeuI/PI-SceI and ligated into I-CeuI/PI-SceI-digested pAdHM41-K7,<sup>19</sup> resulting in pAd-HNF4 $\alpha$ . The human EF-1 $\alpha$  promoter-driven LacZ-, SOX17-, or HEX-expressing Ad vectors, Ad-LacZ, Ad-SOX17, or Ad-HEX, were constructed previously.<sup>7,8,45</sup> Ad-LacZ, Ad-SOX17, Ad-HEX, and Ad-HNF4 $\alpha$ , each of which contains a stretch of lysine residue (K7) peptides in the C-terminal region of the fiber knob for more efficient transduction of human ESCs, iPSCs, and DE cells, were generated and purified as described previously.<sup>7</sup> The VP titer was determined by using a spectrophotometric method.<sup>46</sup>

**LacZ assay.** Human ESC- and iPSC-derived cells were transduced with Ad-LacZ at 3,000 VP/cell for 1.5 hours. After culturing for the indicated number of days, 5-bromo-4-chloro-3-indolyl  $\beta$ -D-galactopyranoside (X-Gal) staining was performed as described previously.<sup>44</sup>

**Flow cytometry.** Single-cell suspensions of human ESCs, iPSCs, and their derivatives were fixed with methanol at 4 °C for 20 minutes and then incubated with the primary antibody, followed by the secondary antibody. Flow cytometry analysis was performed using a FACS LSR Fortessa flow cytometer (BD).

**RNA isolation and reverse transcription-PCR.** Total RNA was isolated from human ESCs, iPSCs, and their derivatives using ISOGENE (Nippon Gene) according to the manufacturer's instructions. Primary human hepatocytes were purchased from CellZDirect, Durham, NC. complementary DNA was synthesized using 500 ng of total RNA with a Superscript VILO cDNA synthesis kit (Invitrogen). Real-time reverse transcription-PCR was performed with Taqman gene expression assays (Applied Biosystems, Foster City, CA) or SYBR Premix Ex Taq (TaKaRa) using an ABI PRISM 7000 Sequence Detector (Applied Biosystems). Relative quantification was performed against a standard curve and the values were normalized against the input determined for the housekeeping gene, glyceraldehyde 3-phosphate dehydrogenase. The primer sequences used in this study are described in **Supplementary Table S1**.

**Immunohistochemistry.** The cells were fixed with methanol or 4% paraformaldehyde (Wako). After blocking with phosphate-buffered saline containing 2% BSA (Sigma) and 0.2% Triton X-100 (Sigma), the cells were incubated with primary antibody at 4 °C for 16 hours, followed by incubation with a secondary antibody that was labeled with Alexa Fluor 488 (Invitrogen) or Alexa Fluor 594 (Invitrogen) at room temperature for 1 hour. All the antibodies are listed in **Supplementary Table S2**.

**Assay for CYP activity.** To measure cytochrome P450 3A4, 2C9, and 1A2 activity, we performed Lytic assays by using a P450-Glo™ CYP3A4 Assay Kit (Promega, Madison, WI). For the CYP3A4 and 2C9 activity assay, undifferentiated human ESCs, the hepatocyte-like cells, and primary human hepatocytes were treated with rifampicin (Sigma), which is the substrate for CYP3A4 and CYP2C9, at a final concentration of 25  $\mu$ mol/l or DMSO (0.1%) for 48 hours. For the CYP1A2 activity assay, undifferentiated human ESCs, the hepatocyte-like cells, and primary human hepatocytes were treated with omeprazole (Sigma), which is the substrate for CYP1A2, at a final concentration of 10  $\mu$ M or DMSO (0.1%) for 48 hours. We measured the fluorescence activity with a luminometer (Lumat LB 9507; Berthold, Oak Ridge, TN) according to the manufacturer's instructions.

**Pyronin Y/Hoechst Staining.** Human ESC-derived cells were stained with Hoechst33342 (Sigma) and Pyronin Y (PY) (Sigma) in Dulbecco's modified Eagle medium (Wako) supplemented with 0.2 mmol/l HEPES and 5% FCS (Invitrogen). Samples were then placed on ice for 15 minutes, and 7-AAD was added to a final concentration of 0.5 mg/ml for exclusion of dead cells. Fluorescence-activated cell-sorting analysis of these cells was

performed on a FACS LSR Fortessa flow cytometer (Becton Dickinson) equipped with a UV-laser.

**Cellular uptake and excretion of ICG.** ICG (Sigma) was dissolved in DMSO at 100 mg/ml, then added to a culture medium of the hepatocyte-like cells to a final concentration of 1 mg/ml on day 20 of differentiation. After incubation at 37°C for 60 minutes, the medium with ICG was discarded and the cells were washed with phosphate-buffered saline. The cellular uptake of ICG was then examined by microscopy. Phosphate-buffered saline was then replaced by the culture medium and the cells were incubated at 37°C for 6 hours. The excretion of ICG was examined by microscopy.

**Periodic Acid-Schiff assay for glycogen.** The hepatocyte-like cells were fixed with 4% paraformaldehyde and stained using a Periodic Acid-Schiff staining system (Sigma) on day 20 of differentiation according to the manufacturer's instructions.

**Cell viability tests.** Cell viability was assessed by Alamar Blue assay kit (Invitrogen). After treatment with test compounds<sup>47–50</sup> (troglitazone, acetaminophen, cyclophosphamide, and carbamazepine) (all from Wako) for 2 days, the culture medium was replaced with 0.5 mg/ml solution of Alamar Blue in culturing medium and cells were incubated for 3 hours at 37°C. The supernatants of the cells were measured at a wavelength of 570 nm with background subtraction at 600 nm in a plate reader. Control refers to incubations in the absence of test compounds and was considered as 100% viability value.

**Uptake of LDL.** The hepatocyte-like cells were cultured with medium containing Alexa-488-labeled LDL (Invitrogen) for 1 hour, and then the cells that could uptake LDL were assessed by immunohistochemistry and flow cytometry.

**Primary human hepatocytes.** Cryopreserved human hepatocytes were purchased from CellzDirect (lot Hu8072). The vials of hepatocytes were rapidly thawed in a shaking water bath at 37°C; the contents of the vial were emptied into prewarmed Cryopreserved Hepatocyte Recovery Medium (CellzDirect) and the suspension was centrifuged at 100g for 10 minutes at room temperature. The hepatocytes were seeded at  $1.25 \times 10^5$  cells/cm<sup>2</sup> in hepatocyte culture medium (Lonza, Walkersville, MD) containing 10% FCS (GIBCO-BRL) onto type I collagen-coated 12-well plates. The medium was replaced with hepatocyte culture medium containing 10% FCS (GIBCO-BRL) 6 hours after seeding. The hepatocytes, which were cultured 48 hours after plating the cells, were used in the experiments.

## SUPPLEMENTARY MATERIAL

**Figure S1.** Genome-wide screening of transcription factors involved in hepatic differentiation emphasizes the importance of the transcription factor HNF4 $\alpha$ .

**Figure S2.** Summary of specific markers for DE cells, hepatoblasts, hepatocytes, cholangiocytes, and pancreas cells.

**Figure S3.** The formation of DE cells, hepatoblasts, hepatocytes, and cholangiocytes from human ESCs.

**Figure S4.** Overexpression of HNF4 $\alpha$  mRNA in hepatoblasts by Ad-HNF4 $\alpha$  transduction.

**Figure S5.** Time course of LacZ expression in hepatoblasts transduced with Ad-LacZ.

**Figure S6.** The morphology of the hepatocyte-like cells.

**Figure S7.** Upregulation of the expression levels of conjugating enzymes and hepatic transporters by HNF4 $\alpha$  transduction.

**Figure S8.** Upregulation of the expression levels of hepatic transcription factors by HNF4 $\alpha$  transduction.

**Figure S9.** Generation of hepatocytes from various human ES or iPSC cell lines.

**Figure S10.** Promotion of MET by HNF4 $\alpha$  transduction.

**Figure S11.** Arrest of cell growth by HNF4 $\alpha$  transduction.

**Table S1.** List of Taqman probes and primers used in this study.

**Table S2.** List of antibodies used in this study.

## ACKNOWLEDGMENTS

We thank Hiroko Matsumura and Misae Nishijima for their excellent technical support. H.M., M.K.F., and T.H. were supported by grants from the Ministry of Health, Labor, and Welfare of Japan. H.M. was also supported by Japan Research foundation For Clinical Pharmacology, The Nakatomi Foundation, and The Uehara Memorial Foundation. K.K. (K. Kawabata) was supported by grants from the Ministry of Education, Sports, Science and Technology of Japan (20200076) and the Ministry of Health, Labor, and Welfare of Japan. K.K. (K. Katayama) and F.S. was supported by Program for Promotion of Fundamental Studies in Health Sciences of the National Institute of Biomedical Innovation (NIBIO).

## REFERENCES

- Thomson, JA, Itskovitz-Eldor, J, Shapiro, SS, Waknitz, MA, Swiergiel, JJ, Marshall, VS *et al.* (1998). Embryonic stem cell lines derived from human blastocysts. *Science* **282**: 1145–1147.
- Takahashi, K, Tanabe, K, Ohnuki, M, Narita, M, Ichisaka, T, Tomoda, K *et al.* (2007). Induction of pluripotent stem cells from adult human fibroblasts by defined factors. *Cell* **131**: 861–872.
- Murry, CE and Keller, G (2008). Differentiation of embryonic stem cells to clinically relevant populations: lessons from embryonic development. *Cell* **132**: 661–680.
- Basma, H, Soto-Gutiérrez, A, Yannam, GR, Liu, L, Ito, R, Yamamoto, T *et al.* (2009). Differentiation and transplantation of human embryonic stem cell-derived hepatocytes. *Gastroenterology* **136**: 990–999.
- Touboul, T, Hannan, NR, Corbinau, S, Martinez, A, Martinet, C, Branchereau, S *et al.* (2010). Generation of functional hepatocytes from human embryonic stem cells under chemically defined conditions that recapitulate liver development. *Hepatology* **51**: 1754–1765.
- Duan, Y, Ma, X, Ma, X, Zou, W, Wang, C, Bahbahan, IS *et al.* (2010). Differentiation and characterization of metabolically functioning hepatocytes from human embryonic stem cells. *Stem Cells* **28**: 674–686.
- Inamura, M, Kawabata, K, Takayama, K, Tashiro, K, Sakurai, F, Katayama, K *et al.* (2011). Efficient generation of hepatoblasts from human ES cells and iPSC cells by transient overexpression of homeobox gene HEX. *Mol Ther* **19**: 400–407.
- Takayama, K, Inamura, M, Kawabata, K, Tashiro, K, Katayama, K, Sakurai, F *et al.* (2011). Efficient and directive generation of two distinct endoderm lineages from human ESCs and iPSCs by differentiation stage-specific SOX17 transduction. *PLoS ONE* **6**: e21780.
- Duncan, SA, Manova, K, Chen, WS, Hoodless, P, Weinstein, DC, Bachvarova, RF *et al.* (1994). Expression of transcription factor HNF-4 in the extraembryonic endoderm, gut, and nephrogenic tissue of the developing mouse embryo: HNF-4 is a marker for primary endoderm in the implanting blastocyst. *Proc Natl Acad Sci USA* **91**: 7598–7602.
- Taraviras, S, Monaghan, AP, Schütz, G and Kelsey, G (1994). Characterization of the mouse HNF-4 gene and its expression during mouse embryogenesis. *Mech Dev* **48**: 67–79.
- Parviz, F, Matullo, C, Garrison, WD, Savatski, L, Adamson, JW, Ning, G *et al.* (2003). Hepatocyte nuclear factor 4alpha controls the development of a hepatic epithelium and liver morphogenesis. *Nat Genet* **34**: 292–296.
- Odom, DT, Zizlsperger, N, Gordon, DB, Bell, GW, Rinaldi, NJ, Murray, HL *et al.* (2004). Control of pancreas and liver gene expression by HNF transcription factors. *Science* **303**: 1378–1381.
- Battle, MA, Konopka, G, Parviz, F, Gaggl, AL, Yang, C, Sladek, FM *et al.* (2006). Hepatocyte nuclear factor 4alpha orchestrates expression of cell adhesion proteins during the epithelial transformation of the developing liver. *Proc Natl Acad Sci USA* **103**: 8419–8424.
- Konopka, G, Tekiel, J, Iverson, M, Wells, C and Duncan, SA (2007). Junctional adhesion molecule-A is critical for the formation of pseudocanaliculi and modulates E-cadherin expression in hepatic cells. *J Biol Chem* **282**: 28137–28148.
- Li, J, Ning, G and Duncan, SA (2000). Mammalian hepatocyte differentiation requires the transcription factor HNF-4alpha. *Genes Dev* **14**: 464–474.
- Hayhurst, GP, Lee, YH, Lambert, G, Ward, JM and Gonzalez, FJ (2001). Hepatocyte nuclear factor 4alpha (nuclear receptor 2A1) is essential for maintenance of hepatic gene expression and lipid homeostasis. *Mol Cell Biol* **21**: 1393–1403.
- Khurana, S, Jaiswal, AK and Mukhopadhyay, A (2010). Hepatocyte nuclear factor-4alpha induces transdifferentiation of hematopoietic cells into hepatocytes. *J Biol Chem* **285**: 4725–4731.
- Suetsugu, A, Nagaki, M, Aoki, H, Motohashi, T, Kunisada, T and Moriwaki, H (2008). Differentiation of mouse hepatic progenitor cells induced by hepatocyte nuclear factor-4 and cell transplantation in mice with liver fibrosis. *Transplantation* **86**: 1178–1186.
- Koizumi, N, Mizuguchi, H, Utoguchi, N, Watanabe, Y and Hayakawa, T (2003). Generation of fiber-modified adenovirus vectors containing heterologous peptides in both the HI loop and C terminus of the fiber knob. *J Gene Med* **5**: 267–276.
- Shiojiri, N (1984). The origin of intrahepatic bile duct cells in the mouse. *J Embryol Exp Morphol* **79**: 25–39.
- Moll, R, Franke, WW, Schiller, DL, Geiger, B and Krepler, R (1982). The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. *Cell* **31**: 11–24.

22. Antoniou, A, Raynaud, P, Cordi, S, Zong, Y, Tronche, F, Stanger, BZ *et al.* (2009). Intrahepatic bile ducts develop according to a new mode of tubulogenesis regulated by the transcription factor SOX9. *Gastroenterology* **136**: 2325–2333.
23. Offield, MF, Jetton, TL, Labosky, PA, Ray, M, Stein, RW, Magnuson, MA *et al.* (1996). PDX-1 is required for pancreatic outgrowth and differentiation of the rostral duodenum. *Development* **122**: 983–995.
24. Sussel, L, Kalamaras, J, Hartigan-O'Connor, DJ, Meneses, JJ, Pedersen, RA, Rubenstein, JL *et al.* (1998). Mice lacking the homeodomain transcription factor Nkx2.2 have diabetes due to arrested differentiation of pancreatic beta cells. *Development* **125**: 2213–2221.
25. Ingelman-Sundberg, M, Oscarson, M and McLellan, RA (1999). Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. *Trends Pharmacol Sci* **20**: 342–349.
26. Henderson, CJ, Otto, DM, Carrie, D, Magnuson, MA, McLaren, AW, Rosewell, I *et al.* (2003). Inactivation of the hepatic cytochrome P450 system by conditional deletion of hepatic cytochrome P450 reductase. *J Biol Chem* **278**: 13480–13486.
27. Yamada, T, Yoshikawa, M, Kanda, S, Kato, Y, Nakajima, Y, Ishizaka, S *et al.* (2002). *In vitro* differentiation of embryonic stem cells into hepatocyte-like cells identified by cellular uptake of indocyanine green. *Stem Cells* **20**: 146–154.
28. Anzenbacher, P and Anzenbacherová, E (2001). Cytochromes P450 and metabolism of xenobiotics. *Cell Mol Life Sci* **58**: 737–747.
29. Zhao, D, Chen, S, Cai, J, Guo, Y, Song, Z, Che, J *et al.* (2009). Derivation and characterization of hepatic progenitor cells from human embryonic stem cells. *PLoS ONE* **4**: e6468.
30. Hatta, K, Takagi, S, Fujisawa, H and Takeichi, M (1987). Spatial and temporal expression pattern of N-cadherin cell adhesion molecules correlated with morphogenetic processes of chicken embryos. *Dev Biol* **120**: 215–227.
31. Shiojiri, N (1981). Enzymo- and immunocytochemical analyses of the differentiation of liver cells in the prenatal mouse. *J Embryol Exp Morphol* **62**: 139–152.
32. Lee, JM, Dedhar, S, Kalluri, R and Thompson, EW (2006). The epithelial-mesenchymal transition: new insights in signaling, development, and disease. *J Cell Biol* **172**: 973–981.
33. Macleod, KF, Sherry, N, Hannon, C, Beach, D, Tokino, T, Kinzler, K *et al.* (1995). p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. *Genes Dev* **9**: 935–944.
34. Si-Tayeb, K, Noto, FK, Nagaoka, M, Li, J, Battle, MA, Duris, C *et al.* (2010). Highly efficient generation of human hepatocyte-like cells from induced pluripotent stem cells. *Hepatology* **51**: 297–305.
35. Sekiya, S and Suzuki, A (2011). Direct conversion of mouse fibroblasts to hepatocyte-like cells by defined factors. *Nature* **475**: 390–393.
36. Huang, P, He, Z, Ji, S, Sun, H, Xiang, D, Liu, C *et al.* (2011). Induction of functional hepatocyte-like cells from mouse fibroblasts by defined factors. *Nature* **475**: 386–389.
37. Satohisa, S, Chiba, H, Osanai, M, Ohno, S, Kojima, T, Saito, T *et al.* (2005). Behavior of tight-junction, adherens-junction and cell polarity proteins during HNF-4 $\alpha$ -induced epithelial polarization. *Exp Cell Res* **310**: 66–78.
38. Xu, ZL, Mizuguchi, H, Sakurai, F, Koizumi, N, Hosono, T, Kawabata, K *et al.* (2005). Approaches to improving the kinetics of adenovirus-delivered genes and gene products. *Adv Drug Deliv Rev* **57**: 781–802.
39. Nagata, S, Toyoda, M, Yamaguchi, S, Hirano, K, Makino, H, Nishino, K *et al.* (2009). Efficient reprogramming of human and mouse primary extra-embryonic cells to pluripotent stem cells. *Genes Cells* **14**: 1395–1404.
40. Makino, H, Toyoda, M, Matsumoto, K, Saito, H, Nishino, K, Fukawatase, Y *et al.* (2009). Mesenchymal to embryonic incomplete transition of human cells by chimeric OCT4/3 (POU5F1) with physiological co-activator EWS. *Exp Cell Res* **315**: 2727–2740.
41. Furue, MK, Na, J, Jackson, JP, Okamoto, T, Jones, M, Baker, D *et al.* (2008). Heparin promotes the growth of human embryonic stem cells in a defined serum-free medium. *Proc Natl Acad Sci USA* **105**: 13409–13414.
42. Mizuguchi, H and Kay, MA (1998). Efficient construction of a recombinant adenovirus vector by an improved *in vitro* ligation method. *Hum Gene Ther* **9**: 2577–2583.
43. Mizuguchi, H and Kay, MA (1999). A simple method for constructing E1- and E1/E4-deleted recombinant adenoviral vectors. *Hum Gene Ther* **10**: 2013–2017.
44. Kawabata, K, Sakurai, F, Yamaguchi, T, Hayakawa, T and Mizuguchi, H (2005). Efficient gene transfer into mouse embryonic stem cells with adenovirus vectors. *Mol Ther* **12**: 547–554.
45. Tashiro, K, Kawabata, K, Sakurai, H, Kurachi, S, Sakurai, F, Yamanishi, K *et al.* (2008). Efficient adenovirus vector-mediated PPAR gamma gene transfer into mouse embryoid bodies promotes adipocyte differentiation. *J Gene Med* **10**: 498–507.
46. Maizel, JV Jr, White, DO and Scharff, MD (1968). The polypeptides of adenovirus. I. Evidence for multiple protein components in the virion and a comparison of types 2, 7A, and 12. *Virology* **36**: 115–125.
47. Smith, MT (2003). Mechanisms of troglitazone hepatotoxicity. *Chem Res Toxicol* **16**: 679–687.
48. Dai, Y and Cederbaum, AI (1995). Cytotoxicity of acetaminophen in human cytochrome P4502E1-transfected HepG2 cells. *J Pharmacol Exp Ther* **273**: 1497–1505.
49. Chang, TK, Weber, GF, Crespi, CL and Waxman, DJ (1993). Differential activation of cyclophosphamide and ifosfamide by cytochromes P-450 2B and 3A in human liver microsomes. *Cancer Res* **53**: 5629–5637.
50. Miao, XS and Metcalfe, CD (2003). Determination of carbamazepine and its metabolites in aqueous samples using liquid chromatography-electrospray tandem mass spectrometry. *Anal Chem* **75**: 3731–3738.